Invivyd Launches 210-Participant Phase 3 LIBERTY Trial of VYD2311 Antibody

Invivyd has initiated dosing of the first participants in its LIBERTY Phase 3 study, a randomized, double-blind trial enrolling approximately 210 healthy adults aged 18 to 49. Participants are randomized 1:1:1 to receive 250 mg VYD2311, an mRNA COVID vaccine, or both doses concurrently to compare safety, tolerability and early immunology readouts.

VYD2311 is a vaccine-alternative monoclonal antibody engineered for intramuscular administration, leveraging Invivyd’s proprietary evolution platform. Prior data suggest a modest reduction in neutralizing titers with co-administration but minimal impact on T-cell responses, supporting its potential as a more tolerable COVID-19 prophylactic.

Invivyd expects to report LIBERTY topline safety and immunogenicity data in Q3 2026, coinciding with pivotal DECLARATION efficacy results. Those datasets are planned to underpin regulatory filings for VYD2311 as an alternative to mRNA vaccination.

LIBERTY is part of the REVOLUTION program, which includes the DECLARATION trial enrolling approximately 2,400 participants to evaluate VYD2311 efficacy in preventing symptomatic COVID-19. Success across these studies could position VYD2311 as a preferred prophylactic option for vulnerable and vaccine-hesitant populations.